These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31870632)

  • 1. Overview of hepatitis C infection, molecular biology, and new treatment.
    Rabaan AA; Al-Ahmed SH; Bazzi AM; Alfouzan WA; Alsuliman SA; Aldrazi FA; Haque S
    J Infect Public Health; 2020 May; 13(5):773-783. PubMed ID: 31870632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
    Merli M; Rossotti R; Travi G; Ferla F; Lauterio A; Angelini Zucchetti T; Alcantarini C; Bargiacchi O; De Carlis L; Puoti M
    Transpl Infect Dis; 2019 Dec; 21(6):e13165. PubMed ID: 31487082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment failure with DAA therapy: Importance of resistance.
    Sarrazin C
    J Hepatol; 2021 Jun; 74(6):1472-1482. PubMed ID: 33716089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Lok AS; Sulkowski MS; Kort JJ; Willner I; Reddy KR; Shiffman ML; Hassan MA; Pearlman BL; Hinestrosa F; Jacobson IM; Morelli G; Peter JA; Vainorius M; Michael LC; Fried MW; Wang GP; Lu W; Larsen L; Nelson DR
    Gastroenterology; 2019 Dec; 157(6):1506-1517.e1. PubMed ID: 31401140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
    N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Pawlotsky JM
    Semin Liver Dis; 2019 Jul; 39(3):354-368. PubMed ID: 31041789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
    Pearlman B; Perrys M; Hinds A
    Am J Gastroenterol; 2019 Sep; 114(9):1550-1552. PubMed ID: 31082871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
    Pearlman BL; Hinds AE
    Aliment Pharmacol Ther; 2018 Nov; 48(9):914-923. PubMed ID: 30288771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Kelley D; Childs-Kean LM
    Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
    Heo YA; Deeks ED
    Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.